Allan Ronald

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5146347/publications.pdf

Version: 2024-02-01

140 papers 9,501 citations

43 h-index 95 g-index

142 all docs $\begin{array}{c} 142 \\ \\ \text{docs citations} \end{array}$

times ranked

142

8428 citing authors

#	Article	IF	Citations
1	Urine Tenofovir Levels Measured Using a Novel Immunoassay Predict Human Immunodeficiency Virus Protection. Clinical Infectious Diseases, 2021, 72, 486-489.	2.9	12
2	Kidney injury biomarkers during exposure to tenofovir-based preexposure prophylaxis. Aids, 2021, 35, 1147-1149.	1.0	1
3	CD101 genetic variants modify regulatory and conventional TÂcell phenotypes and functions. Cell Reports Medicine, 2021, 2, 100322.	3.3	5
4	Impact of Tenofovir-Based Pre-exposure Prophylaxis on Biomarkers of Bone Formation, Bone Resorption, and Bone Mineral Metabolism in HIV-Negative Adults. Open Forum Infectious Diseases, 2019, 6, ofz338.	0.4	3
5	Brief Report: Frequency of Monitoring Kidney Function in HIV-Uninfected Persons Using Daily Oral Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 206-211.	0.9	23
6	Brief Report: Medication Sharing Is Rare Among African HIV-1 Serodiscordant Couples Enrolled in an Efficacy Trial of Oral Pre-exposure Prophylaxis (PrEP) for HIV-1 Prevention. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 184-189.	0.9	5
7	Efficacy of oral pre-exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: a post-hoc analysis of the randomised, placebo-controlled Partners PrEP Study. Lancet HIV,the, 2017, 4, e449-e456.	2.1	44
8	The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion. Aids, 2017, 31, 2007-2016.	1.0	75
9	Effect of Condom Use on Per-act HSV-2 Transmission Risk in HIV-1, HSV-2-discordant Couples. Clinical Infectious Diseases, 2016, 62, civ908.	2.9	21
10	Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 374-380.	0.9	57
11	Younger Age Predicts Failure to Achieve Viral Suppression and Virologic Rebound Among HIV-1-Infected Persons in Serodiscordant Partnerships. AIDS Research and Human Retroviruses, 2016, 32, 148-154.	0.5	32
12	Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women. Journal of Infectious Diseases, 2016, 214, 1050-1057.	1.9	40
13	Seminal HIV-1 RNA Detection in Heterosexual African Men Initiating Antiretroviral Therapy. Journal of Infectious Diseases, 2016, 214, 212-215.	1.9	19
14	HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 579-584.	0.9	68
15	Effect of On-Site Support on Laboratory Practice for Human Immunodeficiency Virus, Tuberculosis, and Malaria Testing. American Journal of Clinical Pathology, 2016, 146, 469-477.	0.4	6
16	Effectiveness of educational outreach in infectious diseases management: a cluster randomized trial in Uganda. BMC Public Health, 2016, 16, 714.	1.2	7
17	Intimate Partner Violence and Adherence to HIV Pre-exposure Prophylaxis (PrEP) in African Women in HIV Serodiscordant Relationships: A Prospective Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 313-322.	0.9	89
18	Comparison of subjective and objective adherence measures for preexposure prophylaxis against HIV infection among serodiscordant couples in East Africa. Aids, 2016, 30, 1121-1129.	1.0	54

#	Article	IF	CITATIONS
19	Regulatory T-Cell Activity But Not Conventional HIV-Specific T-Cell Responses Are Associated With Protection From HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 119-128.	0.9	18
20	Acyclovir Prophylaxis Reduces the Incidence of Herpes Zoster Among HIV-Infected Individuals: Results of a Randomized Clinical Trial. Journal of Infectious Diseases, 2016, 213, 551-555.	1.9	17
21	Transient Increase in Herpes Simplex Virus Type 2 (HSV-2)–Associated Genital Ulcers Following Initiation of Antiretroviral Therapy in HIV/HSV-2–Coinfected Individuals. Journal of Infectious Diseases, 2016, 213, 1573-1578.	1.9	10
22	Frequency of False Positive Rapid HIV Serologic Tests in African Men and Women Receiving PrEP for HIV Prevention: Implications for Programmatic Roll-Out of Biomedical Interventions. PLoS ONE, 2015, 10, e0123005.	1.1	15
23	Changes in Glomerular Kidney Function Among HIV-1 – Uninfected Men and Women Receiving Emtricitabine b>–Tenofovir Disoproxil Fumarate Preexposure Prophylaxis. JAMA Internal Medicine, 2015, 175, 246.	2.6	83
24	Toll-like receptor gene variants and bacterial vaginosis among HIV-1 infected and uninfected African women. Genes and Immunity, 2015, 16, 362-365.	2.2	18
25	Plasma Cytokine Levels and Risk of HIV Type 1 (HIV-1) Transmission and Acquisition: A Nested Case-Control Study Among HIV-1–Serodiscordant Couples. Journal of Infectious Diseases, 2015, 211, 1451-1460.	1.9	47
26	Estimating Efficacy in a Randomized Trial With Product Nonadherence: Application of Multiple Methods to a Trial of Preexposure Prophylaxis for HIV Prevention. American Journal of Epidemiology, 2015, 182, 848-856.	1.6	21
27	Effect of Educational Outreach Timing and Duration on Facility Performance for Infectious Disease Care in Uganda: A Trial with Pre-Post and Cluster Randomized Controlled Components. PLoS ONE, 2015, 10, e0136966.	1.1	1
28	Variants in Host Viral Replication Cycle Genes Are Associated With Heterosexual HIV-1 Acquisition in Africans. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 127-134.	0.9	6
29	Effect of Integrated Capacity-Building Interventions on Malaria Case Management by Health Professionals in Uganda: A Mixed Design Study with Pre/Post and Cluster Randomized Trial Components. PLoS ONE, 2014, 9, e84945.	1.1	22
30	Improving Facility Performance in Infectious Disease Care in Uganda: A Mixed Design Study with Pre/Post and Cluster Randomized Trial Components. PLoS ONE, 2014, 9, e103017.	1.1	21
31	Association between male circumcision and incidence of syphilis in men and women: a prospective study in HIV-1 serodiscordant heterosexual African couples. The Lancet Global Health, 2014, 2, e664-e671.	2.9	32
32	Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. Lancet Infectious Diseases, The, 2014, 14, 1055-1064.	4.6	94
33	Toll-like Receptor Polymorphism Associations With HIV-1 Outcomes Among Sub-Saharan Africans. Journal of Infectious Diseases, 2014, 209, 1623-1627.	1.9	29
34	Disease diagnosis in primary care in Uganda. BMC Family Practice, 2014, 15, 165.	2.9	10
35	Pre-exposure prophylaxis for HIV-1 prevention does not diminish the pregnancy prevention effectiveness of hormonal contraception. Aids, 2014, 28, 1825-1830.	1.0	37
36	An Intervention to Support HIV Preexposure Prophylaxis Adherence in HIV-Serodiscordant Couples in Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 522-529.	0.9	56

#	Article	IF	Citations
37	Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception. Aids, 2014, 28, 2771-2776.	1.0	38
38	Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda. Journal of Antimicrobial Chemotherapy, 2014, 69, 1938-1944.	1.3	3
39	Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment. Neurology, 2013, 80, 196-202.	1.5	61
40	Adherence to Antiretroviral Prophylaxis for HIV Prevention: A Substudy Cohort within a Clinical Trial of Serodiscordant Couples in East Africa. PLoS Medicine, 2013, 10, e1001511.	3.9	192
41	Daily Acyclovir to Decrease Herpes Simplex Virus Type 2 (HSV-2) Transmission from HSV-2/HIV-1 Coinfected Persons: A Randomized Controlled Trial. Journal of Infectious Diseases, 2013, 208, 1366-1374.	1.9	45
42	Plasma Viral Loads During Early HIV-1 Infection Are Similar in Subtype C– and Non-Subtype C–Infected African Seroconverters. Journal of Infectious Diseases, 2013, 207, 1166-1170.	1.9	16
43	Advances in clinical education: a model for infectious disease training for mid-level practitioners in Uganda. International Journal of Infectious Diseases, 2012, 16, e708-e713.	1.5	17
44	Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women. New England Journal of Medicine, 2012, 367, 399-410.	13.9	2,665
45	The Infectious Diseases Institute at Makerere University, Kampala, Uganda. Infectious Disease Clinics of North America, 2011, 25, 369-383.	1.9	8
46	Characteristics of HIV-1 Serodiscordant Couples Enrolled in a Clinical Trial of Antiretroviral Pre-Exposure Prophylaxis for HIV-1 Prevention. PLoS ONE, 2011, 6, e25828.	1.1	75
47	Linkage to HIV Care and Survival Following Inpatient HIV Counseling and Testing. AIDS and Behavior, 2011, 15, 751-760.	1.4	55
48	Emergence of Quinolone Resistance and Cephalosporin MIC Creep in <i>Neisseria gonorrhoeae</i> Isolates from a Cohort of Young Men in Kisumu, Kenya, 2002 to 2009. Antimicrobial Agents and Chemotherapy, 2011, 55, 3882-3888.	1.4	32
49	Diagnostic accuracy of ultrasensitive heat-denatured HIV-1 p24 antigen in non-B subtypes in Kampala, Uganda. International Journal of STD and AIDS, 2011, 22, 310-314.	0.5	6
50	The Prevalence and Causes of Visual Loss Among HIV-Infected Individuals in Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 53, 95-101.	0.9	11
51	Male circumcision and risk of male-to-female HIV-1 transmission: a multinational prospective study in African HIV-1-serodiscordant couples. Aids, 2010, 24, 737-744.	1.0	72
52	Depression symptoms and cognitive function among individuals with advanced HIV infection initiating HAART in Uganda. BMC Psychiatry, 2010, 10, 44.	1.1	129
53	Acyclovir and Transmission of HIV-1 from Persons Infected with HIV-1 and HSV-2. New England Journal of Medicine, 2010, 362, 427-439.	13.9	476
54	First report of Actinobaculum schaalii urinary tract infection in North America. Diagnostic Microbiology and Infectious Disease, 2010, 67, 282-285.	0.8	21

#	Article	IF	Citations
55	Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet, The, 2010, 375, 824-833.	6.3	142
56	Meningitis Caused by Streptococcus suis Serotype 14, North America. Emerging Infectious Diseases, 2009, 15, 350-352.	2.0	33
57	Characteristics of HIV-1 Discordant Couples Enrolled in a Trial of HSV-2 Suppression to Reduce HIV-1 Transmission: The Partners Study. PLoS ONE, 2009, 4, e5272.	1.1	71
58	Three-Year Outcome Data of Second-Line Antiretroviral Therapy in Ugandan Adults: Good Virological Response but High Rate of Toxicity. Journal of the International Association of Providers of AIDS Care, 2009, 8, 52-59.	1.2	24
59	Diagnostic challenges of sexually transmitted infections in resource-limited settings. Future Microbiology, 2009, 4, 1271-1282.	1.0	11
60	Resurrecting the Triple Threat: Academic Social Responsibility in the Context of Global Health Research. Clinical Infectious Diseases, 2009, 48, 1420-1422.	2.9	21
61	HIV Subtype D Is Associated with Dementia, Compared with Subtype A, in Immunosuppressed Individuals at Risk of Cognitive Impairment in Kampala, Uganda. Clinical Infectious Diseases, 2009, 49, 780-786.	2.9	129
62	Clinical presentation and aetiologies of acute or complicated headache among HIV-seropositive patients in a Ugandan clinic. Journal of the International AIDS Society, 2009, 12, 21.	1.2	13
63	Impact of HIV Infection and Kaposi Sarcoma on Human Herpesvirus-8 Mucosal Replication and Dissemination in Uganda. PLoS ONE, 2009, 4, e4222.	1.1	50
64	Infectious diseases: A global human resource challenge. Current Infectious Disease Reports, 2008, 10, 441-443.	1.3	2
65	The Academic Alliance for AIDS Care and Prevention in Africa. Academic Medicine, 2008, 83, 180-184.	0.8	15
66	Outcomes of Cryptococcal Meningitis in Uganda Before and After the Availability of Highly Active Antiretroviral Therapy. Clinical Infectious Diseases, 2008, 46, 1694-1701.	2.9	278
67	Evaluation of Dynabeads and Cytospheres Compared With Flow Cytometry to Enumerate CD4+ T Cells in HIV-Infected Ugandans on Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 48, 297-303.	0.9	23
68	Testing and Counseling. , 2008, , 111-121.		0
69	The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda. African Health Sciences, 2008, 8, 8-12.	0.3	27
70	Predictors of Long-Term Viral Failure Among Ugandan Children and Adults Treated With Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 187-193.	0.9	200
71	The medical management of central nervous system infections in Uganda and the potential impact of an algorithm-based approach to improve outcomes. International Journal of Infectious Diseases, 2007, 11, 524-530.	1.5	26
72	Pattern of neuropsychological performance among HIV positive patients in Uganda. BMC Neurology, 2007, 7, 8.	0.8	69

#	Article	IF	CITATIONS
73	Functional adrenal insufficiency among critically ill patients with human immunodeficiency virus in a resource-limited setting. African Health Sciences, 2007, 7, 101-7.	0.3	17
74	Evaluation of a Low-Cost Method, the Guava EasyCD4 Assay, to Enumerate CD4-Positive Lymphocyte Counts in HIV-Infected Patients in the United States and Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 607-610.	0.9	32
75	HIV Counseling and Testing Practices at an Urban Hospital in Kampala, Uganda. AIDS and Behavior, 2006, 10, 361-367.	1.4	44
76	Localization of Haemophilus ducreyi in naturally acquired chancroidal ulcers. Microbes and Infection, 2006, 8, 2465-2468.	1.0	55
77	Measuring the Outcomes of a Comprehensive HIV Care Course. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 43, 293-303.	0.9	9
78	Reply to Lawn and Wood. Clinical Infectious Diseases, 2006, 42, 432-433.	2.9	3
79	Response to Antiretroviral Therapy in HIV-Infected Patients Attending a Public, Urban Clinic in Kampala, Uganda. Clinical Infectious Diseases, 2006, 42, 252-259.	2.9	91
80	Laboratory Medicine in Africa: A Barrier to Effective Health Care. Clinical Infectious Diseases, 2006, 42, 377-382.	2.9	601
81	Haemophilus ducreyi Infections. , 2006, , 339-340.		O
82	Editorial Commentary: HIV/AIDS Care in Africa Today. Clinical Infectious Diseases, 2005, 40, 1045-1048.	2.9	15
83	Bacterial Interference in the Urinary Tract. Clinical Infectious Diseases, 2005, 41, 1535-1536.	2.9	1
84	Rolling Out Antiretrovirals in Africa: There Are Still Challenges Ahead. Clinical Infectious Diseases, 2005, 41, 386-389.	2.9	18
85	A renal aspergilloma-an unusual presentation of aspergillosis in an HIV patient. African Health Sciences, 2005, 5, 341-2.	0.3	5
86	The International HIV Dementia Scale: a new rapid screening test for HIV dementia. Aids, 2005, 19, 1367-74.	1.0	282
87	The Liver in HIV in Africa. Antiviral Therapy, 2005, 10, 953-965.	0.6	18
88	Monthly Antibiotic Chemoprophylaxis and Incidence of Sexually Transmitted Infections and HIV-1 Infection in Kenyan Sex Workers. JAMA - Journal of the American Medical Association, 2004, 291, 2555.	3.8	227
89	Treatment of HIV/AIDS. JAMA - Journal of the American Medical Association, 2004, 292, 266.	3.8	10
90	Total lymphocyte count of 1200 is not a sensitive predictor of CD4 lymphocyte count among patients with HIV disease in Kampala, Uganda. African Health Sciences, 2004, 4, 94-101.	0.3	20

#	Article	IF	Citations
91	The etiology of urinary tract infection: Traditional and emerging pathogens. Disease-a-Month, 2003, 49, 71-82.	0.4	61
92	Response to Ronald Gray et al., Male circumcision and HIV acquisition and transmission: cohort studies in Rakai, Uganda (AIDS 2000, 14:2371–2381) Aids, 2002, 16, 810-812.	1.0	14
93	Urinary tract infections in adults with diabetes. International Journal of Antimicrobial Agents, 2001, 17, 287-292.	1.1	122
94	Urinary tract infection in adults: research priorities and strategies. International Journal of Antimicrobial Agents, 2001, 17, 343-348.	1.1	139
95	Sexually Transmitted and Urinary Tract Infections. , 2001, , 1623-1641.		0
96	A randomized, placebo-controlled trial of monthly azithromycin prophylaxis to prevent sexually transmitted infections and HIV-1 in Kenyan sex workers: study design and baseline findings. International Journal of STD and AIDS, 2000, 11, 804-811.	0.5	46
97	The Quinolones and Renal Infection. Drugs, 1999, 58, 96-98.	4.9	4
98	A Randomized, Doubleâ€Blind, Placeboâ€Controlled Trial of Singleâ€Dose Ciprofloxacin versus Erythromycin for the Treatment of Chancroid in Nairobi, Kenya. Journal of Infectious Diseases, 1999, 180, 1886-1893.	1.9	53
99	Sexually Transmitted Diseases Services in Societies with Limited Resources. Sexually Transmitted Diseases, 1999, 26, 517-518.	0.8	1
100	Why are syphilis control programs failing?. International Journal of Infectious Diseases, 1998, 2, 121-122.	1.5	3
101	Clinical and in situ cellular responses to Haemophilus ducreyi in the presence or absence of HIV infection. International Journal of STD and AIDS, 1998, 9, 531-536.	0.5	26
102	Editorial Response: Genital Ulceration and Clinical Acumen. Clinical Infectious Diseases, 1997, 25, 299-300.	2.9	7
103	Chancroid, lymphogranuloma venereum and granuloma inguinale. Current Opinion in Infectious Diseases, 1997, 10, 70-74.	1.3	0
104	Risk Factors for Genital Ulcerations in Kenyan Sex Workers. Sexually Transmitted Diseases, 1997, 24, 387-392.	0.8	36
105	COMPLICATED URINARY TRACT INFECTIONS. Infectious Disease Clinics of North America, 1997, 11, 583-592.	1.9	53
106	Sex and Urinary Tract Infections. New England Journal of Medicine, 1996, 335, 511-512.	13.9	12
107	Presumptive specific clinical diagnosis of genital ulcer disease (GUD) in a primary health care setting in Nairobi. International Journal of STD and AIDS, 1996, 7, 201-205.	0.5	29
108	Antimicrobial management of urinary tract infections. Current Opinion in Infectious Diseases, 1995, 8, 420-423.	1.3	1

#	Article	IF	CITATIONS
109	Discussion of A. J. Schaeffer's presentation. Infection, 1994, 22, S30-S30.	2.3	1
110	The management of urinary infections; what have we learned in the past decade?. International Journal of Antimicrobial Agents, 1994, 4, 83-88.	1.1	77
111	Vaccine development for sexually transmitted diseases. Current Opinion in Infectious Diseases, 1992, 5, 44-49.	1.3	O
112	The Nairobi STD Program. Infectious Disease Clinics of North America, 1991, 5, 337-352.	1.9	11
113	HIV infection among lower socioeconomic strata prostitutes in Nairobi. Aids, 1990, 4, 139-144.	1.0	157
114	Geographical Patterns of Male Circumcision Practices in Africa: Association with HIV Seroprevalence. International Journal of Epidemiology, 1990, 19, 693-697.	0.9	193
115	An overview of some mechanisms of bacterial pathogenesis. Canadian Journal of Microbiology, 1988, 34, 281-286.	0.8	15
116	A prospective randomized trial of ceftazidime versus cefazolin/tobramycin in the treatment of hospitalized patients with pneumonia. Journal of Antimicrobial Chemotherapy, 1987, 20, 95-107.	1.3	21
117	Laboratory diagnosis of Haemophilus ducreyi: Sensitivity of culture media. Diagnostic Microbiology and Infectious Disease, 1986, 4, 241-245.	0.8	48
118	Single dose treatment of urinary tract infection in females. Infectious Diseases Newsletter (New York,) Tj ETQq0	0 0 rgBT / 0.2	/Overlock 10 T
119	Trimethoprim sulphamoxole in the treatment of chancroid. Comparison of two single dose treatment regimens with a five day regimen. Journal of Antimicrobial Chemotherapy, 1985, 16, 103-109.	1.3	27
120	Antimicrobial cream susceptibility testing. Burns, 1985, 12, 91-96.	1.1	3
121	Haemophilus ducreyi. Clinical Microbiology Newsletter, 1984, 6, 71-74.	0.4	1
122	Advances in the treatment of urinary tract infection. American Journal of Medicine, 1984, 76, 141-147.	0.6	39
123	Randomized controlled trial comparing trimethoprim/sulfamethoxazole and trimethoprim for infection prophylaxis in hospitalized granulocytopenic patients. American Journal of Medicine, 1984, 76, 223-233.	0.6	35
124	Chancroid: A rediscovered disease. Infectious Diseases Newsletter (New York, NY), 1984, 3, 35-38.	0.2	1
125	ISOLATING HAEMOPHILUS DUCREYI. Lancet, The, 1983, 322, 909-910.	6.3	10
126	Cerebrospinal fluid as a diagnostic body fluid. American Journal of Medicine, 1983, 75, 102-108.	0.6	90

#	Article	IF	CITATIONS
127	Three to eight weeks of therapy with netilmicin: toxicity in normal and diabetic patients. Journal of Antimicrobial Chemotherapy, 1983, 12, 245-248.	1.3	3
128	Treatment of chancroid. A comparison of sulphamethoxazole and trimethoprim-sulphamethoxazole Sexually Transmitted Infections, 1983, 59, 320-324.	0.8	14
129	Single dose treatment of urinary infection. Clinical Microbiology Newsletter, 1982, 4, 35-37.	0.4	O
130	The treatment of chancroid: comparison of one week of sulfisoxazole with single dose doxycycline. Journal of Antimicrobial Chemotherapy, 1979, 5, 261-265.	1.3	19
131	A comparison of the in vitro activity of rosa-micin, erythromycin, clindamycin, metroni-dazole and ornidazole against Haemophilus ducreyl, including \hat{I}^2 -lactamase producing strains. Journal of Antimicrobial Chemotherapy, 1979, 5, 731-734.	1.3	12
132	Antimicrobial misuse—effects and suggestions for control. Journal of Antimicrobial Chemotherapy, 1979, 5, 129-136.	1.3	47
133	A prospective controlled investigation of prophylactic trimethoprim/sulfamethoxazole in hospitalized granulocytopenic patients. American Journal of Medicine, 1979, 66, 248-256.	0.6	269
134	Granulocytopenia in hospitalized patients. American Journal of Medicine, 1978, 64, 121-126.	0.6	83
135	Granulocytopenia in hospitalized patients. American Journal of Medicine, 1978, 64, 127-132.	0.6	46
136	Two cases of Hemophilus endocarditis of prolapsed mitral valvesâ€"Hemophilus paraphrophilus or parainfluenzae?. American Journal of Medicine, 1978, 65, 537-541.	0.6	14
137	Prospective Comparison of Cefoxitin and Cefazolin in Infections Caused by Aerobic Bacteria. Antimicrobial Agents and Chemotherapy, 1978, 13, 255-260.	1.4	9
138	Topical gentamicin cream as prophylaxis against burn-wound sepsis. Burns, 1976, 2, 128-136.	1.1	2
139	Cytosine Arabinoside Therapy for Herpes Simplex Encephalitis—Clinical Experience with Six Patients. Antimicrobial Agents and Chemotherapy, 1973, 3, 412-417.	1.4	37
140	Genital Ulcer Adenopathy Syndrome. , 0, , 433-440.		5